Automatic Tube Compensation (ATC) for Weaning Patients With Severe Neurotoxic Snake Envenoming
NCT ID: NCT00804011
Last Updated: 2008-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
41 participants
INTERVENTIONAL
2004-07-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to evaluate whether a combination of pressure support with automatic tube compensation is superior to PS alone in weaning patients with severe neurotoxic snake envenoming.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Mechanical ventilation is a life-saving intervention and once there is improvement of the underlying indication for mechanical ventilation, it can be withdrawn abruptly in the majority. However, approximately 20-30% of patients still require gradual discontinuation i.e. weaning. This process is not only difficult in patients with chronic respiratory diseases and neuromuscular disorders like neurotoxic snake bite, but is also associated with significant complications like pneumonia, prolonged ICU stay and even mortality, especially in those with persistent weaning failure.
In the mechanically ventilated patient, it has long been recognized that the single greatest cause of imposed work of breathing (WOB) is the resistance caused by the endotracheal tube (ETT). Commonly used maneuvers to overcome the ETT resistance include the use of continuous positive airway pressure (CPAP) or pressure support (PS). However, a new mode of ventilatory support called automatic tube compensation (ATC) delivers exactly the amount of pressure necessary to overcome the resistive load imposed by the endotracheal tube for the flow measured at the time (so called variable pressure support). This mode theoretically can decrease weaning duration and increase the probability of successful extubation by decreasing the WOB.
Recently, we have reported our ICU data of 55 patients of severe neurotoxic snake envenoming in which we evaluated if usage of a higher dosage of SAV offered any significant clinical advantage over a lower dose, and found no difference between the high-dose and low-dose groups. The aim of this study is to evaluate whether a combination of PS with ATC is superior to PS alone in weaning patients with severe neurotoxic snake envenoming.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Automatic tube compensation plus pressure support
ATC
Automatic tube compensation
2
Pressure support alone
PSV
Pressure support ventilation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ATC
Automatic tube compensation
PSV
Pressure support ventilation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Significant improvement in the neuroparalysis with improvement in grade of power to at least MRC 3
* Normal sensorium
* Minimal suction requirements (less than thrice in the eight hours preceding the assessment
* No requirement for any vasoactive drugs
* No sedation (vi) core temperature less than 38.0°C
* Hemoglobin more than 9 gm/dL (viii) systolic blood pressure more than 90 mm Hg
* Overall physician assessment whether the patient is fit for weaning.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dept of Pulmonary Medicine, PGIMER, Chandigarh
UNKNOWN
Post Graduate Institute of Medical Education and Research, Chandigarh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
PGIMER, India
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ritesh Agarwal, MD, DM, FCCP
Role: PRINCIPAL_INVESTIGATOR
PGIMER, INDIA
Ashutosh N Aggarwal, MD, DM, FCCP
Role: STUDY_CHAIR
PGIMER, INDIA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pulmonary Medicine
Chandigarh, Uttarakhand, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS/486/Res/507
Identifier Type: -
Identifier Source: org_study_id